The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease

Nancy Gupta, Sam Papasotiriou, Stephen Hanauer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Introduction: Janus Kinase inhibitors (JAKi) are a new class of oral therapies for the treatment of moderate-severe ulcerative colitis with additional potential for the treatment of moderate-severe Crohn’s disease. In contrast to biologic therapies JAKi provide the opportunity for non-immunogenic once or twice daily oral therapies. Areas covered: Janus Kinase inhibitors for the treatment of ulcerative colitis and Crohn’s disease based on mechanism of action, pharmacokinetics, clinical trial and real-world data regarding safety and efficacy; focusing on regulatory approvals in the U.S. and Europe. Expert opinion: Janus Kinase inhibitors are considered among the ‘advanced therapies’ for IBD and are approved for the treatment of moderate to severe ulcerative colitis in adults with pending approvals for Crohn’s disease in the U.S. JAKi offer non-immunogenic, oral options for patient not responding to other conventional agents but, have been ‘restricted’ by the FDA to patients with inadequate response to TNF blockers. JAKi offer rapidly acting oral alternatives to biologic agents for moderate-severe ulcerative colitis where the risks of cardiovascular and thrombotic events noted in rheumatoid arthritis have not been observed in IBD clinical trials. Nevertheless, monitoring of infections (primarily herpes zoster) and risk factors for cardiovascular and thrombotic complications is appropriate.

Original languageEnglish (US)
Pages (from-to)1075-1089
Number of pages15
JournalExpert Review of Clinical Immunology
Issue number9
StatePublished - 2023


  • Crohn’s disease
  • Inflammatory Bowel Disease
  • Janus kinase inhibitors
  • Tyk2 inhibitors
  • ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this